a public good project by the
Synthesis
Company
of California

© 2026

Michael Rugaard Jensen | doi.page

0 works0 citations0 h-index

Michael Rugaard Jensen

Novartis (Switzerland)(CH)Novartis Institutes for BioMedical ResearchStanford University(US)

Publications by Year

Research Areas

Heat shock proteins research, Cancer-related Molecular Pathways, ATP Synthase and ATPases Research, Computational Drug Discovery Methods, RNA modifications and cancer

Most-Cited Works

→ High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
→ Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity(2004)879 cited
→ Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
→ NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models(2008)222 cited
→ Cyclin G Recruits PP2A to Dephosphorylate Mdm2(2002)210 cited
→ Modelling of the Intake Manifold Filling Dynamics(1996)209 cited

→ Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone(2009)

173 cited

→ Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model(2000)154 cited

Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.(1998)

Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.(1996)